Ozurdex (dexamethasone intravitreal implant) / AbbVie - LARVOL DELTA

12-C-0107: Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma (clinicaltrials.gov) - P2 | N=55 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed | Trial completion date: Jun 2028 ➔ Feb 2025

Trial completion • Trial completion date • Hematological Malignancies • Multiple Myeloma • Neutropenia • Oncology • Smoldering Multiple Myeloma

Switching to Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: Initial Real-World Efficacy Outcomes. (PubMed, J Clin Med) - " This retrospective study included patients from LMU University Hospital who were switched to Faricimab due to an inadequate response or adverse events related to prior intravitreal therapy (Ranibizumab, Aflibercept, or OzurdexTM). Given the small sample size and retrospective design, these findings should be interpreted as exploratory and hypothesis-generating. Further studies are needed to evaluate long-term efficacy and optimal treatment regimens."

Journal • Real-world evidence • Macular Edema • Ophthalmology • Retinal Vein Occlusion

Effect of dexamethasone intravitreal implant on macular edema in vitrectomy eyes (ChiCTR) - P=N/A | N=30 | Not yet recruiting | Sponsor: The second hospital of Dalian Medical University; The second hospital of Dalian Medical University

New trial • Diabetic Macular Edema • Macular Edema • Ophthalmology

Switch to faricimab in various retinal diseases: real-world data (ARVO 2025) - "Previous treatments included bevacizumab, ranibizumab, aflibercept 2mg, brolucizumab, triamcinolone, and Ozurdex. Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Real-world • Real-world evidence • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Outcomes of Diabetic Macular Edema During Pregnancy and the Postpartum (ARVO 2025) - "Nine eyes with pre-pregnancy DME received treatments including bevacizumab (1), Ozurdex (6), and Ranibizumab (2). Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Cataract • Diabetic Macular Edema • Ophthalmology

Incidence, Pathogenesis, Risk Factors, and Treatment of Cystoid Macula Oedema Following Cataract Surgery: A Systematic Review. (PubMed, Diagnostics (Basel)) - "Studies evaluating topical NSAIDs, periocular steroids, intravitreal triamcinolone acetonide (TCA), dexamethasone implants (Ozurdex), and intravitreal bevacizumab were included... Topical NSAIDs, particularly ketorolac and diclofenac, showed effectiveness in acute CMO, while their efficacy in chronic cases was variable... Topical NSAIDs, often combined with periocular steroids, serve as first-line therapy, with periocular steroids offering additional efficacy in resistant cases. Further research is needed to establish optimal treatment algorithms and improve outcomes for patients with post-operative CMO."

Journal • Review • Cataract • Macular Edema • Ophthalmology

Ethnicity & Intraocular pressure (IOP) spike rates of Diabetic Macular Edema (DME) patients: IOP outcomes after 30,172 intravitreal injections from 2014 - 2024 from a single hospital in the United Kingdom (UK) (ARVO 2025) - "IVI agents analysed include Eylea 2 mg (Aflibercept), Vabysmo (Faricimab), Avastin (Bevaziumab), Ongavia (Ranibizumab biosimilar), Lucentis (Ranibizumab), Ozurdex (Dexamethasone implant), Iluvien (Fluocinolone). Insights in the IOP spike rates of various treatment agents used for DME in diverse ethnic populations can inform clinicians on the optimal treatment agent of choice for DME patients. Additionally, it enables tailored risk stratification and patient counselling for shared decision-making."

Clinical • Diabetic Macular Edema • Glaucoma • Ocular Inflammation • Ophthalmology • Optic Neuritis

Ethnicity & Intraocular pressure (IOP) spike rates of Central Retinal Vein Occlusion (CRVO) & Branch Retinal Vein Occlusion (BRVO) patients: IOP outcomes after 26,471 intravitreal injections from 2014-2024 from a single hospital in the United Kingdom (UK) (ARVO 2025) - "IVIs included were: Eylea 2mg (Aflibercept), Ongavia (Ranibizumab biosimilar), Avastin (Bevacizumab), Vabysmo (Faricimab), Lucentis 0.5mg (Ranibuzumab) & Ozurdex (Dexamethasone) implant. Ethnic differences may also influence IVI IOP spikes. Understanding the IOP spike rates in different IVIs used in CRVO & BRVO across different ethnicities may help clinicians in the management of their patients and inform choice of IVI for a more favourable safety profile."

Clinical • Glaucoma • Macular Edema • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

Efficacy of Intravitreal Dexamethasone Implant (Ozurdex®) in Naïve and Refractory Patients with Different Morphological Subtypes of Diabetic Macular Edema. (PubMed, Medicina (Kaunas)) - "All subjects received a single injection of the dexamethasone implant. The presence of SRD was associated with more favorable anatomical results, while CME was associated with better visual acuity. Dexamethasone provided superior results in previously treated patients."

Clinical • Journal • Retrospective data • Diabetes • Diabetic Macular Edema • Macular Edema • Metabolic Disorders • Ophthalmology • Retinal Disorders

Post-operative Fibrinoid Syndrome in Eyes Receiving Dexamethasone Implant (ARVO 2025) - "Purpose Intravitreal dexamethasone implant (Ozurdex®, Allergan Inc., Irvine, CA, USA) and pars-plana vitrectomy (PPV) are both used in the treatment of diabetic retinopathy...Our results showed an incidence of POFS was 3.8%, which is lower than that of previously published data Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Diabetic Retinopathy • Ophthalmology • Retinal Disorders

Travel – associated emissions of intravitreal injections (ARVO 2025) - "Medication included anti-VEGF agents (94%), dexamethasone intravitreal implants (4%), triamcinolone (0.3%), and ganciclovir (2%). Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Age-related Macular Degeneration • Diabetic Macular Edema • Ophthalmology • Wet Age-related Macular Degeneration

Inflammation Targeted Treatment of Diabetic Macular Edema using Optical Coherence Tomography (OCT) Morphology (ARVO 2025) - "The clinical importance of the study is in recognizing eyes with a unique OCT morphology that suggests they may respond well to dexamethasone intravitreal implants. Administering this treatment before or at the start of anti-VEGF treatments, could effectively resolve DME more quickly while reducing both the treatment burden on patients and the overall societal costs."

Diabetic Macular Edema • Ophthalmology

Post-hoc Analysis of Association of Baseline Characteristics and IOP Rise with Dexamethasone Implant in Phase 3 Studies (ARVO 2025) - P3 | "Purpose Dexamethasone intravitreal (IVI) implant 0.7 mg (DEX-I, OZURDEX®), an approved treatment for diabetic macular edema (DME), is associated with increased intraocular pressure (IOP) in ~30% of treated patients...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

P3 data • Retrospective data • Diabetic Macular Edema • Glaucoma • Ophthalmology

Aqueous Humor Cytokines and Imaging Features in Diabetic Macular Edema Treated with Intraocular Steroids with and without Supplemental Anti-Vascular Endothelial Growth Factor Therapy (ARVO 2025) - "Total VEGF concentrations were elevated in the patients that only required ozurdex, but VEGF R2 (Median 621pg/mL DEX, 725pg/mL DEX+IAI) and VEGF R3 (Median 374pg/mL DEX, 419pg/mL DEX+IAI) were higher in the patients the DEX group, while TGFα, in contrast, was lower...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Diabetic Macular Edema • Ocular Inflammation • Ophthalmology • ANGPT1 • FLT4 • IL10 • IL4 • TGFA

Patient Preferences on Same-day Bilateral Intravitreal Dexamethasone Injections (clinicaltrials.gov) - P=N/A | N=200 | Recruiting | Sponsor: Rigshospitalet, Denmark

New trial

Intravitreal Dexamethasone Implant in Vitreoretinal Surgery: An Overview of the Literature. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "This review highlights the increasing role of the DEX implant in vitreoretinal surgery, emphasizing its effectiveness and safety in various surgical and post-surgical settings, while also addressing associated complications."

Journal • Review • Diabetic Macular Edema • Ophthalmology • Retinal Disorders

Use of a multifocal electroretinogram to evaluate the therapeutic effect of a single intravitreal dexamethasone implant, Ozurdex®, for refractory diabetic macular oedema. (PubMed, Int J Retina Vitreous) - "A single intravitreal injection of DEX in refractory DME patients induced significant anatomical and functional improvements, but these improvements only lasted for short periods of up to four months. This treatment exhibited an excellent safety profile. However, at six months, the therapeutic effect was null. The utility of mfERG as a sensitive biomarker of treatment efficacy was highlighted herein."

Journal • Diabetes • Diabetic Macular Edema • Macular Edema • Metabolic Disorders • Ophthalmology

From Monotherapy to Combination Strategies: Redefining Treatment Approaches for Multiple-Cause Macular Edema. (PubMed, Clin Ophthalmol) - "Combination therapies, including anti-VEGF drugs with macular laser photocoagulation, triamcinolone acetonide, or dexamethasone intravitreal implant (Ozurdex), have emerged as promising strategies...Future research directions are outlined, emphasizing the importance of large-scale, long-term studies to evaluate the sustained efficacy and safety of combination therapies. The integration of advanced imaging techniques, biomarker analysis, and innovative therapeutic approaches is expected to shape the future landscape of ME management, moving towards more targeted and effective combination therapies."

Journal • Monotherapy • Review • Diabetic Macular Edema • Inflammation • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

OM: Ozurdex Monotherapy Trial (clinicaltrials.gov) - P4 | N=0 | Withdrawn | Sponsor: Ottawa Hospital Research Institute | N=84 ➔ 0 | Trial completion date: Sep 2027 ➔ Jan 2025 | Recruiting ➔ Withdrawn | Trial primary completion date: Sep 2027 ➔ Jan 2025

Enrollment change • Monotherapy • Trial completion date • Trial primary completion date • Trial withdrawal • Ocular Inflammation • Ophthalmology • Uveitis

Clinical Manifestations of Ocular Toxoplasmosis in Hubei, China: Case Series. (PubMed, Curr Med Sci) - "Primary active retinochoroiditis is the main form of OT in Hubei, China. Timely correct diagnosis on the basis of ocular characteristics and aetiological test results and effective treatment should be adopted to prevent poor visual outcomes and recurrence."

Journal • Cytomegalovirus Infection • Infectious Disease • Inflammation • Ocular Inflammation • Ophthalmology • Uveitis

COHOST: Carbon Monoxide Hyperbaric Oxygen With Steroid Therapy (clinicaltrials.gov) - P1/2 | N=20 | Not yet recruiting | Sponsor: University of Nebraska | Initiation date: Jan 2025 ➔ May 2025

Trial initiation date • CNS Disorders • Movement Disorders • Parkinson's Disease

Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE) (clinicaltrials.gov) - P1/2 | N=0 | Withdrawn | Sponsor: Alfred Chung, MD | N=46 ➔ 0 | Trial completion date: Dec 2027 ➔ Dec 2028 | Recruiting ➔ Withdrawn | Trial primary completion date: Dec 2027 ➔ Dec 2028

Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Amyloidosis

Secondary ocular hypertension as an adverse effect of treatment with intravitreal dexamethasone implant: A retrospective Swedish cohort study. (PubMed, Acta Ophthalmol) - "Our finding that 30.5% of eyes received IOP-lowering treatment confirms that SOHT is a prevalent complication following intravitreal dexamethasone implants. Male gender and higher baseline IOP were key indicators for developing SOHT after Ozurdex® treatment, emphasizing the need for vigilant monitoring. Most cases were managed with IOP-lowering eye drops, indicating that while common, SOHT is typically manageable without invasive interventions."

Adverse events • Journal • Retrospective data • Cardiovascular • Diabetic Macular Edema • Glaucoma • Macular Edema • Ophthalmology • Retinal Vein Occlusion

Management of ocular hypertension following intravitreal dexamethasone implant (ozurdex). (PubMed, Am J Ophthalmol Case Rep) - "Ozurdex-induced OHT can be safely and effectively managed using a combination of medical therapy, laser trabeculoplasty, and angle-based MIGS. This study supports an increasing range of alternative approaches for addressing elevated IOP or postponing surgeries linked with higher risks."

Journal • Cardiovascular • Diabetic Macular Edema • Glaucoma • Ophthalmology • Retinal Vein Occlusion

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma (clinicaltrials.gov) - P2 | N=96 | Suspended | Sponsor: Hackensack Meridian Health | Trial completion date: Jan 2025 ➔ Jan 2026 | Recruiting ➔ Suspended | Trial primary completion date: Jan 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date • Trial suspension • Hematological Malignancies • Multiple Myeloma • Oncology